STOCK TITAN

MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

MIRA Pharmaceuticals (NASDAQ: MIRA) announced new receptor-screening findings for MIRA-55, its investigational oral inflammatory-pain candidate, showing separation from opioid receptor interactions. CB2 activation showed approximately 680-fold separation from mu and 540-fold separation from kappa opioid receptor interactions. No substantial COX-1 or COX-2 inhibition occurred at tested concentrations.

Previously reported animal studies showed greater acute inflammatory pain relief than injected morphine and sustained chronic inflammatory pain relief comparable to celecoxib, with reduced swelling. Animal findings also included brain penetration and no significant THC-like motor impairment. MIRA targets an Investigational New Drug application in the first half of 2027; preclinical work remains ongoing.

Loading...
Loading translation...
10 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Ketamir-2 is advancing toward Phase 2 proof of concept in chemotherapy-induced peripheral neuropathy.
  • Minor pointMIRA-55 CB2 activation showed approximately 680-fold mu and 540-fold kappa opioid receptor separation.
  • Minor pointMIRA-55 showed no substantial COX-1 or COX-2 inhibition at tested concentrations.
  • Minor pointOral MIRA-55 showed greater pain relief than injected morphine in a previously reported acute inflammatory animal model.
  • Minor pointChronic inflammatory animal testing previously showed sustained pain relief comparable to celecoxib and reduced swelling.
5 minor points
  • Minor pointPreviously reported studies demonstrated potent CB2 activation alongside measurable CB1 activity.
  • Minor pointPreviously reported animal studies demonstrated brain penetration after oral MIRA-55 administration.
  • Minor pointFunctional studies showed inhibited agonist-induced β-arrestin recruitment with limited antagonism of Gi/cAMP, two cellular signaling pathways.
  • Minor pointPreviously reported animal studies showed anxiolytic-like effects and exploratory behaviors without significant THC-like motor impairment.
  • Minor point. Forward-looking: it has not happened yet and may not happen.MIRA targets an Investigational New Drug submission in the first half of 2027 for MIRA-55.

Negative

  • None.

Key Figures

Receptor separation: More than 500-fold Mu opioid receptor separation: Approximately 680-fold Kappa opioid receptor separation: 540-fold +1 more
Receptor separation
More than 500-fold
From measured mu, delta, and kappa opioid receptor interactions
Mu opioid receptor separation
Approximately 680-fold
MIRA-55 selectivity findings
Kappa opioid receptor separation
540-fold
MIRA-55 selectivity findings
Targeted IND submission
First half of 2027
MIRA-55 remains in preclinical and IND-enabling activities

Historical Context

1 past event · Latest: Oct 22
1 event
  1. Oct 22

    preclinical pain study

    24h Move
    -7.8%

    MIRA-55 pain relief was comparable to celecoxib in a chronic inflammatory pain study.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cox-1, cox-2, β-arrestin, gi/camp signaling
4 terms
cox-1 medical
"no substantial inhibition of COX-1 or COX-2 at the tested concentrations"
COX‑1 (cyclooxygenase‑1) is an enzyme that converts arachidonic acid into prostaglandin precursors used for normal, ongoing bodily functions such as protecting the stomach lining, supporting kidney blood flow, and enabling platelet aggregation. It is a constitutively expressed isoform of the cyclooxygenase family, so drugs that inhibit COX‑1 reduce those homeostatic prostaglandins and can affect gastric protection and blood clotting.
cox-2 medical
"no substantial inhibition of COX-1 or COX-2 at the tested concentrations"
cox-2 is an enzyme (cyclooxygenase-2, encoded by the PTGS2 gene) that helps make prostaglandins — hormone-like molecules involved in inflammation, pain, fever, and blood flow regulation. It is typically produced at low levels but is strongly increased in injured or inflamed tissues and some tumors; because its activity raises prostaglandin production during inflammation, many anti-inflammatory drugs target COX-2 specifically. COX-2 differs from COX-1, a related enzyme that normally maintains protective functions in the stomach and kidneys, which explains why selective COX-2 inhibitors can reduce inflammation with different side-effect profiles than nonselective drugs.
β-arrestin technical
"distinct effects on β-arrestin and Gi/cAMP signaling"
A β-arrestin is a cellular protein that acts like a traffic cop for cell-surface receptors, stopping or redirecting signals that enter a cell when a drug or natural molecule binds those receptors. Investors care because β-arrestin-driven pathways can change a drug’s effectiveness, side-effect profile, and regulatory outlook; drugs designed to favor or avoid β-arrestin responses can become more competitive or risky in development and approval.
gi/camp signaling technical
"distinct effects on β-arrestin and Gi/cAMP signaling"
Gi/cAMP signaling is a cellular communication pathway where G proteins of the Gi family inhibit the enzyme adenylyl cyclase, lowering levels of the messenger molecule cyclic adenosine monophosphate (cAMP) inside the cell. Lower cAMP changes activity of downstream effectors such as protein kinase A and ion channels, altering processes like neurotransmitter release, heart rate, or hormone responses depending on the cell type; the pathway’s effect depends on which receptor activates Gi and which downstream targets are present in that cell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

New Findings Highlight MIRA-55's Potent CB2 Activation With More Than 500-Fold Separation From Measured Mu, Delta, and Kappa Opioid Receptor Interactions

MIRA-55's Differentiated Profile Combines CB2/CB1 Activity, Brain Penetration, and Distinct Signaling With Encouraging Preclinical Pain Relief, Reduced Inflammation, and Anxiolytic-Like Effects Without Significant THC-Like Motor Impairment

MIAMI, Nov. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced new pharmacological findings for MIRA-55, its investigational oral drug candidate for inflammatory pain.

Expanded receptor screening demonstrated substantial separation between MIRA-55's potent CB2 receptor activation and measured interactions with other biological targets, including approximately 680-fold separation from mu opioid receptors and 540-fold separation from kappa opioid receptors. The compound also showed no substantial inhibition of COX-1 or COX-2 at the tested concentrations, suggesting a selective pharmacological approach distinct from conventional opioid and COX-inhibiting pain or anti-inflammatory medications.

These findings build on MIRA-55's previously reported pharmacological and preclinical results, providing additional support for its development as a potentially differentiated non-opioid treatment for inflammatory pain.

A Potentially Differentiated Mechanism for Inflammatory Pain

MIRA-55's potential differentiation extends beyond activation of a single receptor. Previously reported studies demonstrated potent CB2 activation alongside measurable CB1 activity, two receptors involved in complementary biological pathways associated with pain and inflammation.

CB2 helps regulate inflammation, pain sensitivity, and the body's response to tissue injury, while CB1 plays an important role in how pain signals are transmitted and processed by the nervous system. Together, these activities raise the possibility that MIRA-55 could address both the underlying inflammatory processes contributing to pain and the neurological pathways involved in pain perception.

Previously reported studies also demonstrated that orally administered MIRA-55 reaches brain tissue in animals. This is particularly relevant because pain is not only generated at the site of inflammation but is also processed and regulated by the brain. Brain penetration may therefore provide MIRA-55 with the opportunity to influence central pain-processing pathways in addition to peripheral inflammation.

MIRA-55 has also demonstrated distinct effects on β-arrestin and Gi/cAMP signaling, two pathways through which cannabinoid receptors regulate cellular activity. Functional studies showed inhibition of agonist-induced β-arrestin recruitment with limited antagonism of Gi/cAMP signaling. This distinction may be particularly important because broad disruption of CB1 signaling has been associated with psychiatric adverse effects in previously developed cannabinoid-targeting drugs. MIRA-55's pathway-dependent pharmacology may provide a potential basis for a differentiated CNS behavioral profile. Supporting this possibility, previously reported animal studies demonstrated an anxiolytic-like signal and encouraging exploratory behaviors, alongside the absence of significant THC-like motor impairment.

Previously reported animal studies also demonstrated encouraging analgesic and anti-inflammatory effects. In an acute inflammatory pain model, oral MIRA-55 demonstrated greater pain relief than injected morphine, while a separate chronic inflammatory pain study showed sustained pain relief comparable to celecoxib, alongside reductions in inflammation-associated swelling.

Scientific Perspective

"What makes MIRA-55 particularly compelling is the possibility of addressing pain through complementary biological pathways," said Dr. Itzchak Angel, CSA of MIRA. "Our findings suggest a pharmacological profile that may influence both the inflammatory processes that contribute to pain and how pain signals are processed in the nervous system. The combination of brain penetration, distinct receptor signaling, a broad receptor selectivity profile, and encouraging preclinical efficacy without significant THC-like motor impairment gives us a strong scientific rationale for believing MIRA-55 could represent a differentiated approach to pain treatment."

Management Commentary

"We're building a differentiated pain franchise focused on significant unmet medical needs," said Erez Aminov, CEO of MIRA. "MIRA-55 is designed to address inflammatory pain, while Ketamir-2 targets neuropathic pain and is advancing toward Phase 2 proof of concept in chemotherapy-induced peripheral neuropathy. Our strategy is to translate encouraging science into clinical evidence that can support meaningful treatment options for patients and create long-term value through future strategic partnerships."

Development Outlook

MIRA continues advancing MIRA-55 through preclinical and IND-enabling activities, targeting an Investigational New Drug (IND) submission in the first half of 2027.

Additional preclinical evaluations are ongoing, including measurements of inflammatory cytokines to further characterize MIRA-55's effects on inflammatory signaling.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing novel oral therapies designed to address significant unmet medical needs in pain and metabolic disorders. The Company is building a differentiated pain therapeutics franchise alongside an oral obesity program. Its lead candidate, Ketamir-2, is being developed for neuropathic pain, initially targeting chemotherapy-induced peripheral neuropathy (CIPN). Ketamir-2 has successfully completed Phase 1 clinical testing and is advancing toward Phase 2a under an active IND. MIRA's pipeline also includes MIRA-55, an investigational oral therapy for inflammatory pain, and SKNY-1, an investigational oral therapy for obesity. Following scientific review, the U.S. Drug Enforcement Administration has determined that all three candidates are not classified as controlled substances.

About MIRA-55

MIRA-55 is an investigational novel oral synthetic cannabinoid analog being developed for inflammatory pain. The compound has demonstrated potent CB2 activation, measurable CB1 activity, brain penetration, and distinct receptor signaling across β-arrestin and Gi/cAMP pathways. Preclinical studies have also shown encouraging analgesic and anti-inflammatory activity, anxiolytic-like effects, and exploratory behavioral findings without significant THC-like motor impairment.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking statements should be considered in light of these risks and uncertainties.

Investor and Media Contact

Krystina Quintana
MIRA Pharmaceuticals
info@mirapharma.com 
(786) 432-9792


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MIRA Pharmaceuticals report about MIRA-55 opioid receptor selectivity?

MIRA-55's CB2 activation showed approximately 680-fold separation from mu and 540-fold separation from kappa opioid receptor interactions in expanded screening. The compound also showed no substantial inhibition of COX-1 or COX-2 at the tested concentrations.

When does MIRA plan to submit an Investigational New Drug application for MIRA-55?

MIRA targets an Investigational New Drug submission in the first half of 2027. MIRA-55 remains in preclinical and application-enabling development.

What additional preclinical testing is underway for MIRA-55?

Ongoing MIRA-55 evaluations include measurements of inflammatory cytokines, molecules involved in inflammatory signaling. These evaluations aim to further characterize the candidate's effects on that signaling.

Keep reading